Evidence map›Paper›PMID 20702688›Full record

ArticleAmerican journal of physiology. Cell physiology2010

SV2 regulates neurotransmitter release via multiple mechanisms.

Amy Nowack, Jia Yao, Kenneth L Custer, Sandra M Bajjalieh

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 138 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Observational
  7. Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A).Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Review
  9. Article
  10. Assessing non-invasive quantitative methods for [European journal of nuclear medicine and molecular imaging · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Synaptic Vesicle Glycoprotein 2A Knockout in Parvalbumin and Somatostatin Interneurons Drives Seizures in the Postnatal Mouse Brain.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  20. Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amy NowackDepartment of Pharmacology, University of Washington, Seattle, Washington 98195, USA.
Jia Yao
Kenneth L Custer
Sandra M Bajjalieh
University of Washington · US

Funding

FUNCTIONAL ANALYSIS OF SV2 BY TARGETED GENE DISRUPTIONR01MH059842 · NIMH · UNIVERSITY OF WASHINGTON · PI BAJJALIEH, SANDRA M · 1999 to 2009
$2.9M
NIMH NIH HHS R01 MH 059842
6 · The paper itself

Abstract

Among the proteins that mediate calcium-stimulated transmitter release, the synaptic vesicle protein 2 (SV2) stands out as a unique modulator specific to the neurons and endocrine cells of vertebrates. In synapses, SV2 regulates the expression and trafficking of the calcium sensor protein synaptotagmin, an action consistent with the reduced calcium-mediated exocytosis observed in neurons lacking SV2. Yet SV2 contains amino acid motifs consistent with it performing other actions that could regulate presynaptic functioning and that might underlie the mechanism of drug action. To test the role of these functional motifs, we performed a mutagenic analysis of SV2A and assessed the ability of mutant SV2A proteins to restore normal synaptic transmission in neurons from SV2A/B knockout mice. We report that SV2A-R231Q, harboring a mutation in a canonical transporter motif, restored normal synaptic depression (a measure of release probability and signature deficit of neurons lacking SV2). In contrast, normal synaptic depression was not restored by SV2A-W300A and SV2A-W666A, harboring mutations of conserved tryptophans in the 5th and 10th transmembrane domains. Although they did not rescue normal neurotransmission, SV2A-W300A and SV2A-W666A did restore normal levels of synaptotagmin expression and internalization. This indicates that tryptophans 300 and 666 support an essential action of SV2 that is unrelated to its role in synaptotagmin expression or trafficking. These results indicate that SV2 performs at least two actions at the synapse that contribute to neurotransmitter release.

Indexed as

AnimalsCells, CulturedExocytosisMembrane GlycoproteinsMiceMice, KnockoutMutationNerve Tissue ProteinsNeuronsNeurotransmitter AgentsPatch-Clamp TechniquesProtein IsoformsRecombinant Fusion ProteinsSynapsesSynaptic TransmissionMembrane GlycoproteinsNerve Tissue ProteinsNeurotransmitter AgentsProtein IsoformsRecombinant Fusion ProteinsSv2a protein, mouse

Identifiers

PMID20702688
PMCPMC2980308
OpenAlexW2164282704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.